CSI’s Strategic Approach to Mitigating Clinical Trial Supply Disruption Recent developments in U.S. trade policy are shaking up supply...

This month, we are focusing on Oncology and have reflected on the notable advancements to oncology medications in recent years....

How CSI supplied large quantities of ruxolitinib to a biotech’s ongoing Phase 3 oncology study involving 14 countries, nine depots and 67...

Oncology products monopolise the list of best-selling drugs. With a huge range of indications that is only growing, therapies become more specific to tumour or cell pathologies and increasing patient numbers. Several oncology products now have ‘blockbuster’ status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster produc